Merck Cozaar profit sharing

Executive Summary

Dupont will receive 50% of Cozaar operating profits in North America starting Feb. 1, Merck Investor Relations Senior Director Laura Jordan announces Jan. 23. Existing Dupont royalties on Merck's losartan products Cozaar and Hyzaar will remain unchanged. Dupont receives 10% of profits from sales of the hypertension products. The profit sharing will give Dupont its largest source of revenue as the chemical company moves forward with plans to spin off the Rx business. Cozaar/Hyzaar revenues in the U.S. totaled $770 mil. in 2000